JNJ

Operational sales grew 6% in the third quarter of 2026. Full-year operational sales guidance increased to $100.7 billion at the midpoint.

When tech stocks crack, most investors discover too late that their portfolios were far more concentrated than they realized.

Health Rounds: Glucose monitoring devices for type 2 diabetes benefit even those not on insulin

A dividend that keeps growing beats a fat yield that gets cut, but only if the company can actually afford to keep raising it.

China pricing and European budget cuts were cited among the pressures behind a MedTech consensus miss that sent Johnson & Johnson shares lower. JNJ investors with losses can request a review.

Johnson & Johnson raises its 2026 sales and earnings outlook as strong pharmaceutical growth offsets MedTech challenges, while 2027 dilution clouds the outlook.

Johnson and Johnson crushed earnings, raised guidance, and still watched its stock crater nearly 6% in a single session. Understanding what spooked investors reveals whether Tuesday's selloff is a trap or a warning.

Every big pharma company eventually watches its best-selling drug go generic, yet some keep raising their dividends anyway.

Johnson & Johnson executive vice president and CFO Joe Wolk discusses the company's third-quarter earnings, raising its full-year guidance, a potential spinoff of its DePuy Synthes orthopedics unit, and more, on 'The Claman Countdown.' #fox #foxbusiness #media #breakingnews #us #usa #new #news #breaking #theclamancountdown #claman #johnsonandjohnson #business #finance #financial #stocks #stockmarket #wallstreet #investing #investment #earnings #corporate #healthcare #health #medical #orthopedics #medicaldevices #depuy #spinoff #revenue #profits #guidance #economy #market #leadership #innovation #pharmaceuticals

Healthcare giants UnitedHealth Group and Johnson & Johnson reported Q3 results on Tuesday, with both raising their full-year earnings outlooks but delivering contrasting reports.